Our Company

BioMed Valley Discoveries, Inc., is a for-profit, disease-related research and development organization, whose mission is to address unmet medical needs in areas that are considered too early, too unconventional or too unprofitable for traditional biotech and pharmaceutical companies. Operating since 2007, BVD advances its mission with commercial capabilities and resources typically unavailable to academic institutions. As a member of the Stowers Group of Companies, BVD receives its funding principally from an endowment supporting the Stowers Institute for Medical Research, a non-profit 550-person basic biomedical research organization. One hundred percent of the profits from BVD accrue to the benefit of the Stowers Institute.

Recent News

Press release: "Bacterial biosurgery shows promise for reducing the size of inoperable tumors" August 13, 2014
Read More

Publication: “Clostridium novyi-NT induces anti-tumor responses” Science Translational Medicine August 13, 2014: Vol 6, Issue 249, p. 249ra111 Abstract

More news

Portfolio Highlights

  • 3
    Fast growing tumors exceed
    blood supply and leave an
    anaerobic center
    Newly discovered bacterial spores
    thrive in anaerobic environment
    and target tumor's center
    C. Novyi-NT consumes
    anaerobic cells of tumor
  • 2
    Ligand binding
    activates extracellular
    Mutations in MAPK pathway result
    in excessive signaling
    BVD-523 inhibits
    aberrant signaling
    in the MAPK pathway
    Cell Proliferation,
    Growth, and Survival

"To wrest from nature the secrets which have perplexed philosophers in all ages, to track to their sources the causes of disease, to correlate the vast stores of knowledge, that they may be quickly available for the prevention and cure of disease - these are our ambitions."

-William Osler, 1904

  • Oncolytic bacteria may provide significant benefit to patients with solid tumors. Read MoreFrequently Asked Questions
  • ERK inhibition may provide benefit to patient cancers which are dependent on MAPK pathway mutations. Read More